Drug search by name

Denosumab Injection (Prolia) and Hypocalcemia

Result of checking the interaction of drug Denosumab Injection (Prolia) and disease Hypocalcemia for safety when used together.

Check result:

Denosumab Injection (Prolia) <> Hypocalcemia

Relevance: 23.07.2019 Reviewer: Shkutko P.M., M.D., in

When checking interaction based on authoritative sources Drugs.com, Rxlist.com, Webmd.com, Medscape.com there are contraindications or side effects that may cause harm or increase the negative effect from drug use in presence of concomitant diseases.

Consumer:

Preexisting hypocalcemia must be corrected prior to initiating treatment with denosumab. Caution should be exercised in patients predisposed to hypocalcemia and any disturbances of mineral metabolism, such as history of hypoparathyroidism, thyroid or parathyroid surgery, malabsorption syndromes, excision of small intestine, severe renal impairment or dialysis. Clinical monitoring of calcium and mineral levels (phosphorus and magnesium) are highly recommended within 14 days of denosumab injection. It is important to maintain calcium levels with adequate calcium and vitamin D supplementation.

Denosumab Injection (Prolia)

Generic Name: denosumab

Brand Name: Prolia, Xgeva

Synonyms: Denosumab

What is Denosumab Injection (Prolia)?